Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan : vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
BACKGROUND: This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan.
METHODS: We conducted a test-negative case-control study. We included medically attended episodes and hospitalizations involving individuals aged ≥16 with signs and symptoms from July to November 2022, when Omicron BA.5 was dominant nationwide. To evaluate VE, we calculated adjusted ORs of vaccination among test-positive versus test-negative individuals using a mixed-effects logistic regression.
RESULTS: For VE against symptomatic infections among individuals aged 16 to 59, VE of primary vaccination at > 180 days was 26.1% (95% CI: 10.6-38.8%); VE of the first booster was 58.5% (48.4-66.7%) at ≤90 days, decreasing to 41.1% (29.5-50.8%) at 91 to 180 days. For individuals aged ≥60, VE of the first booster was 42.8% (1.7-66.7%) at ≤90 days, dropping to 15.4% (-25.9-43.2%) at 91 to 180 days, and then increasing to 44.0% (16.4-62.5%) after the second booster. For VE against severe diseases, VE of the first and second booster was 77.3% (61.2-86.7%) at ≤90 days and 55.9% (23.4-74.6%) afterward.
CONCLUSION: mRNA booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert review of vaccines - 23(2024), 1 vom: 14. Jan., Seite 213-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maeda, Haruka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BA.5 |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14760584.2024.2310807 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367793199 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367793199 | ||
| 003 | DE-627 | ||
| 005 | 20240214233203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14760584.2024.2310807 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM367793199 | ||
| 035 | |a (NLM)38288980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maeda, Haruka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan |b vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan | ||
| 520 | |a METHODS: We conducted a test-negative case-control study. We included medically attended episodes and hospitalizations involving individuals aged ≥16 with signs and symptoms from July to November 2022, when Omicron BA.5 was dominant nationwide. To evaluate VE, we calculated adjusted ORs of vaccination among test-positive versus test-negative individuals using a mixed-effects logistic regression | ||
| 520 | |a RESULTS: For VE against symptomatic infections among individuals aged 16 to 59, VE of primary vaccination at > 180 days was 26.1% (95% CI: 10.6-38.8%); VE of the first booster was 58.5% (48.4-66.7%) at ≤90 days, decreasing to 41.1% (29.5-50.8%) at 91 to 180 days. For individuals aged ≥60, VE of the first booster was 42.8% (1.7-66.7%) at ≤90 days, dropping to 15.4% (-25.9-43.2%) at 91 to 180 days, and then increasing to 44.0% (16.4-62.5%) after the second booster. For VE against severe diseases, VE of the first and second booster was 77.3% (61.2-86.7%) at ≤90 days and 55.9% (23.4-74.6%) afterward | ||
| 520 | |a CONCLUSION: mRNA booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BA.5 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Japan | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a monovalent | |
| 650 | 4 | |a vaccine effectiveness | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Saito, Nobuo |e verfasserin |4 aut | |
| 700 | 1 | |a Igarashi, Ataru |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Mayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Masuda, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Osawa, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hosokawa, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Kamura, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Imura, Haruki |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuzaka, Suguru |e verfasserin |4 aut | |
| 700 | 1 | |a Sugimoto, Yukihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwamitsu, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Motohashi, Iori |e verfasserin |4 aut | |
| 700 | 1 | |a Morikawa, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Oda, Rentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshina, Yuiko |e verfasserin |4 aut | |
| 700 | 1 | |a Matono, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Teshigahara, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Sando, Eiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Asami, Sadaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Kudo, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Akizuki, Noboru |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Yoshikazu |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Tomoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kishaba, Tomoo |e verfasserin |4 aut | |
| 700 | 1 | |a Ohara, Yasuji |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Yoshinao |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Motoi |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Konosuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of vaccines |d 2002 |g 23(2024), 1 vom: 14. Jan., Seite 213-225 |w (DE-627)NLM126545200 |x 1744-8395 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:14 |g month:01 |g pages:213-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14760584.2024.2310807 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 14 |c 01 |h 213-225 | ||